Compare Summit Therapeutics Inc (SMMT) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs US Bancorp — how do they compare? Summit Therapeutics Inc trades at $17.34 (market cap $13.71B), while US Bancorp trades at $56.81 (market cap $88.86B). The key difference: US Bancorp is far larger — about 6.5× Summit Therapeutics Inc's market cap, and US Bancorp pays a 3.79% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and US Bancorp for 97 Days on average.
| SMMT | USB | |
|---|---|---|
Market Cap | $13.71B | $88.86B |
Volume | 6,173,057 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $26.38 | $65.42 |
52-Week Low | $12.43 | $45.28 |
Typical Hold Time | 16 Days | 97 Days |
Enterprise Value | $13.04B | $118.35B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
U.S. Bancorp (USB) trades at $56.81, up 1.14% today, but technical indicators are bearish with moving averages signaling a downtrend. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Fundamentals show strong profitability with a 27.61% net income margin and a modest P/E of 11.38. The company recently raised its dividend by 3.8% to $0.54 per share, reflecting confidence in its financial health.
The outlook is mixed: analyst consensus is bullish with a $69.94 price target, but near-term technical weakness and macroeconomic sensitivity pose risks. Upside potential hinges on continued earnings outperformance and stable interest rates, while downside risks include regulatory changes and economic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
